NEW YORK (GenomeWeb News) – British molecular diagnostics company QuantuMDx has closed an $8.4 million investment round to further the development of a device for point-of-care testing, the firm said today.

Private investors and the University of Newcastle upon Tyne contributed to the round, which will support the optimization of Q-POC, QuantuMDx's handheld DNA sequencing and genotyping device, and allow the company to flesh out its R&D team and advisory board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.